Barka: Russian researchers have discovered that a modified form of the CRYAB protein-which accumulates in the cells of diabetes patients-actively dismantles the toxic protein clusters associated with Parkinson's disease, opening a promising new avenue for therapeutic development.
According to Oman News Agency, the Russian Science Foundation announced that the finding could significantly accelerate the creation of novel medications targeting Parkinson's, a progressive neurodegenerative disorder affecting millions worldwide.
Professor Vladimir Muronets of Moscow State University's Institute of Physics and Biochemistry described the research as transformative, offering an unprecedented understanding of the biological link between diabetes and Parkinson's while illuminating strategies to harness the brain's innate defensive mechanisms during the earliest phases of neurodegeneration.
The study further indicates that the CRYAB protein's characteristics can be deliberately modulated through targeted genetic mutations, offering a flexible platform for therapeutic intervention. Scientists explain that CRYAB serves a vital protective function, preserving protein structure under heat stress-conditions frequently triggered by infectious diseases. Abundantly present in the eye's lens and various cell types, including cerebral neurons, the protein is known to help stave off Parkinson's progression.
The research team focused on structural changes in CRYAB and its interaction with toxic peptide aggregates within cells of Parkinson's patients also afflicted with diabetes. They postulated that elevated glucose levels could prompt reactions between carbohydrate derivatives and CRYAB, profoundly reshaping the protein's architecture.
Testing this hypothesis, the investigators tracked interactions between CRYAB molecules and methylglyoxal, a glucose byproduct that accumulates in diabetic cells. Experiments revealed that while the modified protein offers diminished protection against thermal stress to other proteins, it gains a critical countervailing ability: it potently suppresses the formation of toxic alpha-synuclein aggregates.
Consequently, individual alpha-synuclein strands coalesce into irregular clusters that are approximately one-third less harmful to cells than the dangerous aggregates typically implicated in Parkinson's pathology. The researchers express hope that elucidating this mechanism will not only expedite the development of new Parkinson's therapies but also deepen understanding of how diabetes influences the trajectory of other chronic diseases.